A few highlights:-
1991 Founded Cytocell, a molecular diagnostics company; raised £8 M and ran the company which commercialised technology in-licensed from the University of Oxford. In 2014 Cytocell was acquired by Oxford Gene Technology
2002 Helped start up BioAnalab, a University of Oxford spin-out which provided analytical services to the pharma industry and was part time CEO until 2003. The company was acquired giving the investors an excellent return.
2004 Co-founder, and then CEO of CMP Therapeutics Ltd a company founded on Medical Research Council technology – a novel compound for treatment of allergies and infectious diseases. Raised £5 M and took the compound from the lab through to completion of Phase II clinical trials. Stepped down in 2010.
2007 Working with H2O ventures to create 360 Genomics, a molecular diagnostics company, where he was Chairman. The company was acquired by a listed diagnostics company in 2013.
2010-13 CEO and then Chairman of Alchemy Pharmatech a company with a novel nasal drug delivery technology. He raised £450 k and helped take the product through to the start of trials.
In addition to these and other company activities Bruce is a director of a small investment fund and a Board Member of the European Diagnostics Clusters Alliance.